source
- J&J's IBD combo therapy misses statistical goal but will be tested in a focused patient subgroupJohnson & Johnson reported that its experimental combination of Tremfya and Simponi, called JNJ-4804, did not achieve a statistically significant improvement in a Phase 2b study of inflammatory bow…
- Pharma's reputation among patient groups edges up to 57% but access and pricing concerns lingerPatient groups surveyed by research firm PatientView gave drugmakers a 57% “good” or “excellent” reputation rating, the highest level since 2023. The survey covered more than 2,400 groups in 35 cou…